ARTICLE SUMMARY:
A wide-ranging discussion with J&J’s EVP and Worldwide Chairman of Medical Devices on how she plans to get Johnson & Johnson’s medtech mojo back.
Fifteen years ago, when Johnson & Johnson launched its historic $20 billion-plus offer for Guidant Corp., many medtech industry executives quietly cheered, if only because, they argued, it suggested the value that the healthcare giant was willing to place on medical devices.
